论文部分内容阅读
据上海、沈阳、重庆及天津等四个地区453例重症肝炎资料分析,急性重症肝炎占8.8％(40/453),亚急性重症肝炎(亚重肝)占91.2％(413/453),因此我国重症肝炎症人中,亚重肝占绝大多数。亚重肝病人的肝脏病理损害程度不一,其临床表现、病情严重程度随之差异,对治疗的反应亦不相同。当今有关重症肝炎的治疗药物、治疗方法种类繁多,其疗效评价各家意见亦不一致,所以本文研究了亚重肝的临床分型和分型治疗。
According to the analysis of 453 cases of severe hepatitis in Shanghai, Shenyang, Chongqing and Tianjin, acute severe hepatitis accounts for 8.8% (40/453) and subacute severe hepatitis (sub-liver) accounts for 91.2% (413/453) Severe hepatitis in China, the majority of sub-heavy liver. Hepatic disease in patients with varying degrees of liver damage, its clinical manifestations, the severity of the disease with the difference, the response to treatment is not the same. Today’s treatment of severe hepatitis drugs, a wide range of treatment methods, evaluation of their effectiveness is not the same all opinions, so this article studies the clinical classification of sub-heavy liver and sub-type treatment.